Targeting Aurora kinase A suppresses the growth of human oral squamous cell carcinoma cells in vitro and in vivo

Oral Oncology

Volumn 49, Issue 6, 2013, Pages 551-559

  Tanaka, Hiroshi ^a   Nakashiro, Koh Ichi ^a,b   Iwamoto, Kazuki ^a   Tokuzen, Norihiko ^a   Fujita, Yohei ^a   Shirakawa, Rikimaru ^a   Oka, Ryota ^a   Goda, Hiroyuki ^a   Hamakawa, Hiroyuki ^a,b  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b EHIME UNIVERSITY   (Japan)

Author keywords

AURKA; MLN8237; Molecular targeted therapy; Oral squamous cell carcinoma; siRNA

Indexed keywords

AURORA A KINASE; MESSENGER RNA; SMALL INTERFERING RNA;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; LYMPH NODE METASTASIS; MICROARRAY ANALYSIS; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

AURORA KINASE A; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL LINE, TUMOR; DNA PRIMERS; HUMANS; MOUTH NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER; TISSUE ARRAY ANALYSIS;

EID: 84877072690     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2013.02.002     Document Type: Article

References (32)

1. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 12 2010 2893 2917
2. S. Gupta, W. Kong, Y. Peng, Q. Miao, and W.J. Mackillop Temporal trends in the incidence and survival of cancers of the upper aerodigestive tract in Ontario and the United States Int J Cancer 125 9 2009 2159 2165
3. I.B. Weinstein Addiction to oncogenes-the Achilles heel of cancer Science 297 5578 2002 63 64
4. B.J. Druker, F. Guilhot, S.G. O'Brien, I. Gathmann, H. Kantarjian, and N. Gattermann Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 23 2006 2408 2417
5. G.D. Demetri, M. von Mehren, C.D. Blanke, A.D. Van den Abbeele, B. Eisenberg, and P.J. Roberts Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 7 2002 472 480
6. O. Gautschi, J. Heighway, P.C. Mack, P.R. Purnell, P.N. Lara Jr, and D.R. Gandara Aurora kinases as anticancer drug targets Clin Cancer Res 14 6 2008 1639 1648
7. J. Fu, M. Bian, Q. Jiang, and C. Zhang Roles of Aurora kinase in mitosis and tumorigenesis Mol Cancer Res 5 1 2007 1 10
8. J.A. Pérez Fidalgo, D. Roda, S. Roselló, E. Rodríguez-Braun, and A. Cervantes Aurora kinase inhibitors: a new class of drug targeting the regulatory mitotic system Clin Transl Oncol 11 12 2009 787 798
9. D.S. Boss, J.H. Beijnen, and J.H. Schellens Clinical experience with Aurora kinase inhibitors: a review Oncologist 14 8 2009 780 793
10. S. Shintani, M. Mihara, Y. Nakahara, T. Aida, T. Tachikawa, and H. Hamakawa Lymph node metastasis of oral cancer visualized in live tissue by green fluorescent protein expression Oral Oncol 38 7 2002 664 669
11. S.K. Klosek, K. Nakashiro, S. Hara, H. Goda, and H. Hamakawa Stat3 as a molecular target in RNA interference-based treatment of oral squamous cell carcinoma Oncol Rep 20 4 2008 873 878
12. S. Shintani, H. Hamakawa, K. Nakashiro, T. Shirota, M. Hatori, and M. Tanaka Friend leukaemia insertion (Fli)-1 is a prediction marker candidate for radiotherapy resistant oral squamous cell carcinoma Int J Oral Maxillofac Surg 39 11 2010 1115 1119
13. X. Zhao, F.C. Li, Y.H. Li, W.N. Fu, D.F. Huang, and Y. Ye Mutation of p53 and overexpression of STK15 in laryngeal squamous cell carcinoma Zhonghua Zhong Liu Za Zhi 27 3 2005 134 137
14. F.C. Li, Y.H. Li, X. Zhao, N. Kang, W.N. Fu, and Z.M. Xu Deletion of p15 and p16 genes and overexpression of STK15 gene in human laryngeal squamous cell carcinoma Zhonghua Yi Xue Za Zhi 83 4 2003 316 319
15. R. Reiter, P. Gais, U. Jütting, M.K. Steuer-Vogt, A. Pickhard, and K. Bink Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma Clin Cancer Res 12 17 2006 5136 5141
16. A. Mazumdar, Y.C. Henderson, A.K. El-Naggar, S. Sen, and G.L. Clayman Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma Head Neck 31 5 2009 625 634
17. D. Zhang, T. Hirota, T. Marumoto, M. Shimizu, N. Kunitoku, and T. Sasayama Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary gland of mouse models Oncogene 23 54 2004 8720 8730
18. D. Zhang, T. Shimizu, N. Araki, T. Hirota, M. Yoshie, and K. Ogawa Aurora A overexpression induces cellular senescence in mammary gland hyperplastic tumor developed in p53-deficient mice Oncogene 27 31 2008 4305 4314
19. N. Stransky, A.M. Egloff, A.D. Tward, A.D. Kostic, K. Cibulskis, and A. Sivachenko The mutational landscape of head and neck squamous cell carcinoma Science 333 6046 2011 1157 1160
20. N. Agrawal, M.J. Frederick, C.R. Pickering, C. Bettegowda, K. Chang, and R.J. Li Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1 Science 333 6046 2011 1154 1157
21. M. Kollareddy, D. Zheleva, P. Dzubak, P.S. Brahmkshatriya, M. Lepsik, and M. Hajduch Aurora kinase inhibitors: progress towards the clinic Invest New Drugs 30 6 2012 2411 2432
22. J.M. Maris, C.L. Morton, R. Gorlick, E.A. Kolb, R. Lock, and H. Carol Initial testing of Aurora kinase A inhibitor MLN8237 by the pediatric preclinical testing program (PPTP) Pediatr Blood Cancer 55 1 2010 26 34
23. M. Tomita, and N. Mori Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T-cells in vitro Cancer Sci 101 5 2010 1204 1211
24. G. Görgün, E. Calabrese, T. Hideshima, J. Ecsedy, G. Perrone, and M. Mani A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma Blood 115 25 2010 5202 5213
25. M.G. Manfredi, J.A. Ecsedy, A. Chakravarty, L. Silverman, M. Zhang, and K.M. Hoar Characterization of alisertib (MLN8237), an investigational small-molecule inhibitor of Aurora A kinase using novel in vivo pharmacodynamic assays Clin Cancer Res 17 24 2011 7614 7624
26. A. Cervantes, E. Elez, D. Roda, J. Ecsedy, T. Macarulla, and K. Venkatakrishnan Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective Aurora A kinase inhibitor, in patients with advanced solid tumors Clin Cancer Res 18 17 2012 4764 4774
27. E.C. Dees, R.B. Cohen, M. von Mehren, T.E. Stinchcombe, H. Liu, and K. Venkatakrishnan Phase I study of Aurora kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations Clin Cancer Res 18 17 2012 4775 4784
28. P. Mu, S. Nagahara, N. Makita, Y. Tarumi, K. Kadomatsu, and Y. Takei Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer Int J Cancer 125 12 2008 2978 2990
29. T. Ochiya, Y. Takahama, S. Nagahara, Y. Sumita, A. Hisada, and H. Itoh New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet Nature Med 5 6 1999 707 710
30. Y. Minakuchi, F. Takeshita, N. Kosaka, H. Sasaki, Y. Yamamoto, and M. Kouno Atelocollagen-mediated systemic small interfering RNA delivery for effective gene silencing in vitro and in vivo Nucl Acid Res 32 13 2004 e109
31. K. Azuma, K. Nakashiro, T. Sasaki, H. Goda, J. Onodera, and N. Tanji Anti-tumor effect of small interfering RNA targeting androgen receptor in human androgen-independent prostate cancer cells Biochem Biophys Res Commun 391 1 2010 1075 1079
32. T. Sasaki, K. Nakashiro, H. Tanaka, K. Azuma, H. Goda, and S. Hara Knockdown of Akt isoform by RNA silencing suppress the growth of human prostate cancer cells in vitro and in vivo Biochem Biophys Res Commun 399 1 2010 79 83